-
RW Baird Downgrades CERS To Neutral
Friday, March 4, 2011 - 7:33am | 56Analysts at RW Baird downgrade Cerus Corporation (NASDAQ: CERS) from “outperform” to “neutral.” The target price for CERS has been lowered from $4 to $3. CERS shares gained 2.44% to close at $3.36 yesterday. More Analyst Ratings here
-
Cerus Corporation Reports Fourth Quarter and Year-End 2010 Results
Thursday, March 3, 2011 - 5:06pm | 114Cerus Corporation (NASDAQ: CERS) today announced financial results for the fourth quarter and year ended December 31, 2010. Total revenue for the year ended December 31, 2010 was $23.1 million, an increase of $5.1 million, or 29%, from the same period in 2009. Product revenue for 2010 was $21.7...
-
The Cooper Companies Announces First Quarter 2011 Results
Thursday, March 3, 2011 - 5:05pm | 144The Cooper Companies, Inc. (NYSE: COO) today announced financial results for the fiscal first quarter ended January 31, 2011. Revenue increased 13% year-over-year to $293.2 million. CooperVision (CVI) revenue up 13% to $243.6 million and CooperSurgical (CSI) revenue up 12%...
-
Benchmark Reports STAAR Surgical's Q4 Revenue Beat Eclipsed by Accelerating Spending but 2011 Continues to Look Promising
Wednesday, March 2, 2011 - 9:21am | 154According to Benchmark, STAAR Surgical Corporation's (NASDAQ: STAA) Q4 revenue was eclipsed by accelerating spending but 2011 continues to look promising. Benchmark reported that revenue in 4Q10 expanded 8.3% to $14.4 million, which exceeded the $14.2 million consensus and Benchmark forecast. “Loss...
-
Morgan Keegan Maintains Outperform on Cooper Companies (COO)
Wednesday, March 2, 2011 - 8:52am | 130Morgan Keegan is out with its report today on Cooper Companies (NYSE: COO), maintaining Outperform. In a note to clients, Morgan Keegan writes, "With Cooper's 1Q earnings to be announced on March 3, we expect no downward revision to management's fiscal 2011 EPS guidance of $3.30-$3.50 following the...
-
STAAR Surgical Reports Q4 EPS of $(0.02) vs. $0.01
Tuesday, March 1, 2011 - 5:08pm | 103STAAR Surgical Company (Nasdaq: STAA) today reported results for the fourth quarter and full year ended December 31, 2010. Revenue for the fourth quarter increased 8% to $14.4 million, primarily reflecting growth in core product (IOLs and ICLs) revenue of 7%. The Company generated cash from...
-
Horizon Lines Appoints Stephen H. Fraser as Interim CEO
Thursday, February 24, 2011 - 2:12pm | 140Horizon Lines, Inc. (NYSE: HRZ) today announced that the company's Board of Directors has named Alex J. Mandl to the position of Chairman and appointed Stephen H. Fraser as interim President and Chief Executive Officer (CEO), succeeding Chairman, President and Chief Executive Officer Charles G. "...
-
Protection Bought on Alcon, Inc. (ACL)
Wednesday, February 23, 2011 - 11:52am | 143Shares of Alcon, Inc. (NYSE: ACL) are higher on the session by 0.12%, currently trading at $165.47. The stock has been moving largely higher over the past four months and is currently trading above the 50-day and 200-day moving averages. Options traders are buying puts on the name today. A short...
-
Morning Market Movers (WBNK, DEP, BDCO, ELGX)
Wednesday, February 23, 2011 - 11:01am | 149Waccamaw Bankshares Inc (NASDAQ: WBNK) jumped 25.39% to $1.4420 at 10:00 am. WBNK shares have dipped 56.44% over the past 52 weeks, while the S&P 500 index has gained 20.18% in the same period. Duncan Energy Partners LP (NYSE: DEP) shares advanced 22.97% to $40.04. Enterprise Products Partners...
-
Top 4 Small-Cap Stocks In The Semiconductor-Broad Line Industry With The Highest EPS (TRIB, BLUD, NEOG, ABAX)
Tuesday, February 22, 2011 - 4:17am | 134Below are the top small-cap diagnostic substance stocks on the NYSE and the NASDAQ in terms of earnings per share. The trailing-twelve-month earnings per share at Trinity Biotech plc (NASDAQ: TRIB) is $2.80. TRIB's ROE for the same period is 56.37%. The trailing-twelve-month earnings per share at...
-
UPDATE: Piper Jaffray Raises PT on Merit Medical Systems to $24 (MMSI)
Friday, February 18, 2011 - 8:33am | 158Piper Jaffray is out with its report today on Merit Medical Systems (NASDAQ: MMSI), raising its price target from $20 to $24. In a note to clients, Piper Jaffray writes, "Merit reported robust Q4 results with both sales and adjusted EPS coming in ahead of our thinking. In addition, management...
-
Piper Jaffray Raises PT On Merit Medical Systems To $24
Friday, February 18, 2011 - 7:53am | 28Piper Jaffray has raised the price target on Merit Medical Systems (NASDAQ: MMSI) from $20 to $24 and maintains its Overweight rating.
-
Jefferies Downs WST To Hold
Friday, February 18, 2011 - 7:47am | 49Analysts at Jefferies downgrade West Pharmaceutical Services Inc (NYSE: WST) from “buy” to “hold.” The target price for WST is set to $43. WST shares fell 1.06% to close at $41.03 yesterday. More Analyst Ratings here
-
Cynosure Up 12.5% On Revenue Beat (CYNO)
Tuesday, February 15, 2011 - 3:10pm | 217Shares of Westford, Massachusetts-based Cynosure, Inc. (Nasdaq: CYNO) are currently up 12.5% at $13.44 per share during Tuesday afternoon trading. Today's trading range for shares of Cynosure, Inc has been between $12.00 and $13.75 per share, approaching the 52-week high of $14.06. The consensus...
-
Endologix Announces Presentation of Favorable Initial PEVAR Trial Results
Tuesday, February 15, 2011 - 12:52pm | 87Endologix, Inc. (Nasdaq: ELGX), developer of minimally invasive treatments for aortic disorders, announced today the presentation of the initial clinical results from the PEVAR Trial at the 2011 iCON (International Congress of Endovascular Specialists) annual meeting in Scottsdale, Arizona. Among...